Find an expert

Professor Coral Gartner is an international expert in tobacco control policy and the world's leading expert on electronic nicotine delivery systems (or e-cigarettes). She is the Director of the NHMRC Centre of Research Excellence on Achieving the Tobacco Endgame (Tobacco Endgame CRE), an Australian Research Council Future Fellow, and the Chair of the Interdisciplinary Tobacco Endgame Research Network, the country lead Investigator for Australia with the International Tobacco Control Policy Evaluation Project (ITC Project), and a Co-Investigator with the SewAUs Wastewater Epidemiology Project. She is currently the Director of Research at the University of Queensland's School of Public Health, the Regional Editor for Australasia for the BMJ journal, Tobacco Control, after serving as a senior editor from 2012-2018. She is the immediate Past President of the Oceania Chapter of the Society for Research on Nicotine and Tobacco (SRNT-O).

She leads a multidisciplinary research team of international experts (located in Australia, New Zealand, Canada, the USA, England, and the Netherlands) to develop the evidence base for tobacco endgame strategies and to identify the most promising policies that could end the cigarette epidemic in Australia, and beyond. Her research program includes consideration of how these policies could be implemented, while mitigating potential unintended impacts and increasing equity. Her research methods span cohort studies, clinical trials, policy analyses, simulation modelling and mixed methods research.

Professor Gartner joined the University of Queensland in 2006. With undergraduate qualifications in environmental health and a PhD in environmental epidemiology, she completed a postdoctoral fellowship on tobacco control policy and held a NHMRC Career Development Fellowship (2014-2018). In 2019, she led the development of UQ’s flagship cross-faculty postgraduate programs in Environmental Health Sciences.

Professor Gartner has published over 300 academic works, including journal articles, book chapters, and submissions to government inquiries, and has served as an expert witness to a number of government inquiries and consultations. She has also authored articles on tobacco control topics for The Conversation.

Wendy Goodwin is a registered veterinarian in Queensland and has worked for the University of Queensland as a clinical anesthetist since 2010. She received her veterinary degree from the University of Queensland in 2004 and in 2013 was awarded a Doctorate of Philosophy by the University of Queensland for her research thesis ‘Studies of Alfaxalone in Horses’. In 2008 she was awarded Membership of the Australian & New Zealand College of Veterinary Scientists in Equine Medicine and in 2013 was awarded Membership in Veterinary Anaesthesia and Critical Care. In 2016 Wendy sucessfully became a Fellowship of the Australian & New Zealand College of Veterinary Scientists in Veterinary Anaesthesia and Critical Care.

Wendy is passionate about veterinary anaesthesia and analgesia and has dedicated the majority of her professional career to pursuing excellence in this field. Her clinical anaesthetic experience has covered a wide range of species including horses, small animal companion animals, farm animals, avian and exotic animals and animals used in scientific research. Wendy has a strong research interest and is keen to further explore research and development opportunities in the veterinary and medical sectors. She has papers published in peer reviewed scientific journals and presented her research findings at international conferences relating to veterinary anaesthesia and pain management.

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

• Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
• The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson’s disease pathophysiology
• Therapeutic targeting of the gut-brain axis for neuroprotection
• Drug discovery, development and repositioning for novel therapeutic targets
• Discovery and validation of clinical biomarkers for PD and ALS
• Clinical trials for disease-modifying therapeutic strategies

Hebe Gouda is an epidemiologist with research experience in Papua New Guinea, Indonesia and Egypt. She has a Masters of Public Health and a PhD from the University of Cambridge. She currently focuses on three related streams of research including: 1) Measuring mortality and disease burden with a particular focus on the epidemiological transition in low and middle income countries; 2) Evaluating health systems approaches and responses to population health burdens and 3) Measurement, data and information: the ethics and epistemology of population health research methods.

Professor Gray is a Senior Researcher at the Centre for Health Services Research within the Faculty of Medicine.

He has formal training in medicine as a specialist geriatrician and in health administration. Previously he held senior management positions in the public health system in Victoria, in general management and aged care services. He joined academia full time at UQ in 2002. He directed the Centre for Health Services Research in its foundational period 2017-22. He now leads a vibrant research program that focuses on system level improvements within aged care.

His research interests focus on aged care policy, models of aged care service delivery, assessment and care planning systems, and in recent years, health informatics and telemedicine strategies.

He leads international development of hospital systems, and is a Board member and the Australian coordinator for interRAI, a multinational research collaborative.

Judith Greer is an immunologist with a strong interest in the nervous system and autoimmune diseases affecting the nervous system.

She is a graduate of the University of Queensland, having completed her PhD on cancer immunology. She then undertook postdoctoral training at Harvard Medical School in the USA, during which time her interests shifted towards immune responses and interactions within the nervous system (neuroimmunology), an area in which she has worked ever since. She isa Principal Research Fellow at the UQ Centre for Clinical Research, located at the Royal Brisbane & Women's Hospital.

Her research is directly particularly towards trying to identify brain components that are targetted by the immune system in people with a variety of disorders, particularly multiple sclerosis (MS), which is traditionally thought to be an autoimmune disease, but also in psychosis, where we are now starting to understand that autoimmune targetting of the brain can play a role in some patients. She is interested in how the specificity of autoimmune responses within the nervous system relates to the symptoms experienced by patients, and in developing new ways to specifically turn off the damaging immune responses in the brain. Another focus of her research is to improve on pre-clinical models of MS, so as to enhance the translation of new therapeutic approaches for MS to the clinic.

Judith is also interested in research training, and held leadership positions in this area in the School of Medicine and the Faculty of Medicine at UQ from 2000 - 2023. She is also committed to improving the field of neuroimmunology, and has been a member of the International Advisory Board of the International Society for Neuroimmunology and is the Asia-Pacific representative for the Global Schools of Neuroimmunology. Judith co-founded a society, Neuroimmunology Australia, to better support those working in this field, and was Convenor and Chair of the 14th International Congress of Neuroimmunology, which was held in Brisbane in 2018 (the only time this congress has been held outside of the Northern Hemisphere).

Ristan is an Honorary Associate Professor School of Medicine Southern Clinical School and MRI-UQ. Previously she has been Senior Biostatistician at Mater Research and Senior Lecturer in Epidemiology and Biosecurity with the School of Veterinary Science UQ. She is an epidemiologist, medical researcher and veterinarian who has been involved in medical and veterinary clinical research, academic teaching and veterinary practice for over 25 years. She completed her Bachelor of Arts majoring in Pure Mathematics in 1972, Bachelor of Veterinary Science in 1979, Master of Veterinary Science in 1995, PhD in the School of Medicine, The University of Queensland in 2004, and membership of the Epidemiology Chapter of the Australia and New Zealand College of Veterinary Scientists in 2005. Her areas of research interest include Congenital Hyperinsulinism of Infancy, bone metabolism in Cystic Fibrosis, Vitamin D in Type 1 Diabetes, as well as study design and data analysis. These latter interests have led to collaborations with clinicians and scientists in a wide variety of fields of research, for example human viral respiratory infection, paediatric liver disease, Pseudomonas spp infection in humans and horses, and many others. Since 1990, Dr Greer has been variously a lecturer and researcher with The University of Queensland School of Medicine, Queensland Children’s Medical Research Institute and affiliated institutions, and taught epidemiology in the School of Veterinary Science where she inaugurated the first course in research methodology for postgraduate students.

Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.

Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.

As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.

In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.

Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

Prof Lisa Hall is Professor in Epidemiology at the University of Queensland in Brisbane, Australia.

Teaching: Lisa has experience lecturing at both undergraduate and postgraduate levels, in a range of public health and research methods courses. She is a Senior Fellow of the Higher Education Academy. At UQ she was the Director of Teaching and Learning within the School of Public Health from 2021-2024.

Research: Lisa is an active health services researcher with expertise in epidemiology, implementation science and economic evaluation. Lisa’s work examines not only the effectiveness, but also the cost-effectiveness, feasibility and sustainability of health services. Her current research focuses on the interface between evidence, policy and implementation to improve the surveillance and prevention of healthcare associated infections.

Prof Hall’s research is pragmatic and “Real world”. It is multidisciplinary and collaborative, with an emphasis on translation. She has established active multidisciplinary collaborations with a wide range of leading researchers, policymakers and clinicians. Since 2013, A/Prof Hall has been named as a Chief Investigator on grants and consultancies worth over $19 million. Key grants include:

• Researching Effective Approaches to Cleaning in Hospitals (REACH): A national stepped wedge trial of examining the cost-effectiveness of an environmental cleaning bundle. This NHMRC Partnership Grant project with the Wesley Medical Research Institute used an implementation science framework to improve uptake of best practice cleaning approaches by environmental services staff.
• National Centre for Infections in Cancer – This NHMRC Centre of Research Excellence, has now received Synergy grant funding. Based at the Peter MacCallum Cancer Centre in Melbourne, it aims at improving infection surveillance and prevention in cancer patients. This is novel work examining what clinical guidelines, therapeutics and surveillance approaches should be implemented to improve monitoring and survival in this vulnerable patient population.
• “There's no place like home”: national scale up of the paediatric low risk febrile neutropenia program - National collaborative project based out of Murdoch Children’s Research Institute – MRFF funded
• General Practitioner Antimicrobial Stewardship Programme Study (GAPS Trial). A cluster randomised trial examining the economic and clinical effectiveness of a multi-modal intervention to reduce antibiotic prescribing in primary care. Collaboration between UQ, QUT and Bond with Commonwealth Department of Health funding.
• Development of the Monitoring and Evaluation Framework for the National Antimicrobial Resistance Strategy - Commonwealth Department of Health funding

Policy Experience: Lisa has significant policy experience at statewide and national levels. Prior to returning to academia in 2013, Lisa was a senior manager at the state health department of Queensland - responsible for the design, implementation and evaluation of infection prevention programs and policy. She was a technical expert on the Australian Commission of Safety and Quality in Healthcare (ACSQHC) Healthcare Associated Infection Advisory Committee, a role she has held continuously from 2009 to 2024.

Wayne Hall is Emeritus Professor at the National Centre for Youth Substance Use Research (NCYSUR) at the University of Queensland (January 2021-). He was a Visiting Professor at the National Addiction Centre, Kings College London (2009-2019), the London School of Hygiene and Tropical Medicine (2010-2021); and the National Drug and Alcohol Research Centre, UNSW (since 2001).

Wayne was formerly Professorial Fellow (2017-2020) in and Director of the National Centre for Youth Substance Abuse Research (2014-2016), an NHMRC Australia Fellow in addiction neuroethics at the University of Queensland Centre for Clinical Research and the Queensland Brain Institute, UQ (2009-2015); Professor of Public Health Policy in the School of Population Health (2005-2010); Director of the Office of Public Policy and Ethics at the Institute for Molecular Bioscience (2001-2005) at the University of Queensland; and Director of the National Drug and Alcohol Research Centre, UNSW (1994-2001).

In 2016 Wayne was made a Fellow of the Academy of Health and Medical Sciences. Wayne has advised the World Health Organization on: the health effects of cannabis use; the effectiveness of drug substitution treatment; the scientific quality of the Swiss heroin trials; the contribution of illicit drug use to the global burden of disease; and the ethical implications of genetic and neuroscience research on addiction.

CURRENT POSITIONS

· Senior Staff Specialist (Public Health Medicine), Queensland Health

· Principal Research Fellow, Centre for Clinical Research - University of Queensland

RECENT POSITIONS

· General Practitioner, Indooroopilly General Practice

· Director, Queensland Centre for Intellectual and Developmental Disability (to January 2021)

· Senior Medical Officer, Mater Intellectual Disability and Autism Service (to November 2020)

· General Practitioner, Cornwall Street Medical Centre (to November 2020)

Colorectal Surgeon Brisbane

Associate Professor Meredith Harris is a researcher in the field of mental health services research and evaluation. She is a Principal Research Fellow with the School of Public Health at the University of Queensland, based at the Queensland Centre for Mental Health Research.

Meredith holds qualifications in psychology, policy and applied social research, and public health. She has over 25 years of experience in the management and administration of research projects, including systematic literature reviews, cross-sectional and longitudinal studies, studies based on epidemiological survey data, and evaluations of health programs and interventions using observational, quasi-experimental and experimental research designs.

Meredith's current role is with the Analysis and Reporting Component of the Australian Mental Health Outcomes and Classification Network (AMHOCN), which leads the design, analysis and reporting of the National Outcomes and Casemix Collection (http://www.amhocn.org/). In this role, she is leading a range of projects designed to improve the measurement of patient- and service-level outcomes in Australia's specialised public sector mental health services.

Carmel Hawley MBBS, FRACP, M.Med.Sci, is a Senior Staff Specialist and Director of Haemodialysis Services at Princess Alexandra Hospital. In addition, she is an Associate Professor (A/P) of Medicine at the School of Medicine, University of Queensland and current (inaugural) Chair for the Australasian Kidney Trials network (AKTN) formed in 2005. Under A/P Hawley’s stewardship, AKTN’s research output is now recognised internationally for its quality and impact. This has driven major advances in the evidence base, that directly informs care and outcomes for people living with chronic kidney disease. A/P Hawley also holds a Master’s degree in Biostatistics, has expertise in trial management, methodology, design and conduct. She is currently involved in numerous industry-led and/or investigator initiated international and national clinical trials as either a Principal or Associate Investigator, providing leadership and direction to emerging early and mid-career researchers.

Helen works across a range of projects in both the research and consultancy arms of the Centre for Online Health, Centre for Health Services Research. Her focus is on the effective use of technology to increase access to health interventions (e.g. online psychoeducational tools for carers; telehealth implementation, telemental health and allied health) and increasing health literacy in the community (e.g. dementia knowledge and digital health). She is particularly interested in using health technology to promote quality end-of-life care. Her current projects aim to increase care closer to home for people with dementia and with life-limiting illnesses (e.g. telepalliative care). In 2023, she was awarded a 3-year National Palliative Care Project Grant funding to lead a national palliative care telementoring project - Palliative Care ECHO. Other research includes: evaluation of telepalliative care services (e.g. patient/ carer outcomes and perceptions and staff perceptions); mental health interventions via telehealth and social media and; online psychoeducational support for carers of people with primary brain tumours in order to increase quality of life and mental wellbeing.

Helen coordinates a range of COH consultancy projects.

She is a Registered Psychologist with clinical experience working with a range of issues and diverse populations and has over ten years’ experience teaching and facilitating workshops on psychology and health communication.

A/Prof Ingrid Hickman is a Principal Research Fellow in Implementation Science with the UQ ULTRA team (Clinical Trial Capability) located within the Centre for Clinical Research in Herston. A/Prof Ingrid Hickman is an implementation scientist and has over 20 years experience in health services clinical research. Her career has focused on research excellence, strategic leadership and translating scientific evidence into improved clinical care for people with complex chronic conditions. From randomised controlled trials and mechanisms of disease progression through to patient centred co-design of health services, her collaborative approach to research aims to find solutions to health care problems. Prior to taking up the role with the ULTRA team, A/Prof Hickman led the Metabolic Obesity Research Group and the Nutrition Research Program at the Princess Alexandra Hospital in Brisbane for over 12 years. Within this role she has been a passionate advocate for embedding implementation science and methodologies into clinical trials and health services research and has been recognised internationally for her investment in implementation science and clinical workforce capacity building in research translation.